The objective of this study was to determine short-and long-term cardiovascular outcomes in unselected patients with diabetes mellitus (DM) with acute ischemic chest pain (AICP). In patients with DM presenting to the emergency department with AICP, short-term cardiovascular outcomes remain discordant between trials and registries, whereas longterm outcomes are not well-described. A consecutive cohort of all residents of Olmsted County, Minnesota, presenting with AICP from January 1, 1985, to December 31, 1992, was followed for a median duration of 16.6 years. In long-term follow-up, data from a pooled analysis of Thrombolysis In Myocardial Infarction (TIMI) trials demonstrated that diabetes mellitus (DM) was associated with higher mortality at 1 year than the absence of DM.
In long-term follow-up, data from a pooled analysis of Thrombolysis In Myocardial Infarction (TIMI) trials demonstrated that diabetes mellitus (DM) was associated with higher mortality at 1 year than the absence of DM. 1 This increased risk for death was also observed in a large international registry at 2 year, which also documented a higher risk for subsequent heart failure (HF). 2 The longest follow-up of mortality for patients with DM with non-ST elevation acute coronary syndromes (ACS) is 4 years. 3 Despite this evidence, and the recognition that DM is 1 of the most important risk variables in the causation of coronary artery disease, DM is not currently included as an independent high-risk variable in national and international risk assessment guidelines for patients presenting with suspected ACS. 4, 5 We present findings from a unique community-based cohort of consecutive patients with non-ST elevation ACS, with and without DM, who were followed for Ͼ15 years.
Methods
Using written screening logs, we retrospectively identified all residents of Olmsted County, Minnesota, presenting to 1 of the county's 3 emergency rooms with acute chest pain from January 1, 1985 , to December 31, 1992. The complete medical records of all county residents presenting with their first episodes of acute chest pain consistent with unstable coronary syndromes during the study period were reviewed by an experienced nurse abstractor. This was defined according to the diamond classification as follows: new onset or worsening pattern of ischemic chest pain, occurring at rest or with minimal exertion, and alleviated by sublingual nitroglycerin and/or rest. 6 Patients were excluded if they had electrocardiographic results suggestive of ST-segment elevation myocardial infarctions (MIs) or definitive alternative causes for chest pain, including pulmonary embolism, pneumonia, musculoskeletal pain, pericarditis, or dissecting aortic aneurysm. Patients with DM were identified from notations in their medical records that included recorded diagnoses in their medical histories and the use of antihyperglycemic medications. Patients with type 1 and type 2 DM were included.
For all eligible patients, complete medical records were abstracted to determine the history of the qualifying epi-sodes, including detailed physical examination findings, as well as medical histories. This was carried out through the resources of the Rochester Epidemiology Project. 7 The qualifying electrocardiogram was interpreted by a staff cardiologist from the Mayo Clinic and verified by 1 of the study physicians. Using the Agency for Health Care Policy and Research (AHCPR) criteria, which form the basis for chest pain clinical risk stratification in the current American College of Cardiology and American Heart Association guideline, 4, 8 patients were classified into high-, intermediate-, and low-risk categories. Patients subsequently ruling in for MI, with creatine kinase-MB or creatine kinase levels Ͼ2 times the upper limit of normal any time within the first 24 hours of emergency department presentation, were classified into the evolving MI group. Troponin levels were not available during the study period. Long-term data were collected in 2 phases. In the first phase, major adverse cardiovascular and cerebrovascular events (MACCEs), including death, MI, stroke, and need for revascularization, were measured. Study subjects who did not have ongoing medical care visits in Olmsted County were contacted to determine vital status. The first phase of long-term patient follow-up ended September 29, 1998. In the second phase, last known alive dates or death dates as of January 2007 were added. Death dates were obtained through Minnesota and Olmsted County death records. Thirty-seven patients were excluded at this time for refusal to allow the use of their records for research purposes.
Continuous data were compared between patients with and without DM using Student's t test and are presented as means and ranges. Categorical data were compared using Pearson's chi-square test and are summarized as frequency (percentage). Survival rates were estimated using KaplanMeier methods and were compared using the log-rank test. Logistic regression models were used to estimate unadjusted and partial (adjusted) odds ratios (ORs) between DM and other risk factors and 30-day events. Cox proportionalhazards models were used to estimate the marginal and partial effects of DM and other risk factors on follow-up mortality and MACCEs. Interactions between age and DM and between gender and DM were investigated and retained if statistically significant and omitted if not. Covariate risk factors were included if they had significant unadjusted associations with the end point. No variable selection was done except for the aforementioned testing for interactions.
Results
There were 6,801 residents of Olmsted County who presented to emergency rooms with their first episodes of acute chest pain during the study period (January 1, 1985 to December 31, 1992). Of these, 2,271 (33.4%) met the eligibility criteria for non-ST elevation ACS and were followed as study subjects for a median of 7.3 years for MACCEs. Of the ineligible patients, cardiac causes accounted for 6.7% of patients, including ST-segment elevation MIs in 5.5%, stable angina in 1.0%, and aortic dissection in 0.2%. Noncardiac causes of chest pain accounted for 36.2% of patients, 23.9% of patients were excluded because of indeterminate causes, 17.6% because they were nonresidents, and 15.6% for other reasons. After extending the follow-up data for vital status, 2,234 study subjects were followed for a median of 16.6 years.
Of the 2,271 patients, 336 (14.8%) had previously diagnosed DM. with DM were also more likely to have hypertension, use aspirin, and have electrocardiographic abnormalities. However, they were less likely to be smokers. In unadjusted analysis, patients with DM were more likely to have MACCEs in the short term (Table 2) . At 30 days, 14 patients with DM (4.2%) compared with 43 (2.2%) without DM (p ϭ 0.035) had died and were also more likely to have had strokes. No stroke events were related to percutaneous coronary intervention. Thirty-three patients with DM (9.8%) had HF at 30 days compared with 60 without DM (3.1%) (p Ͻ0.001) at 30 days, with HF defined as a clinical diagnosis on the basis of symptoms of dyspnea on exertion, orthopnea, and fatigue. In multivariate modeling, DM was no longer associated with 30-day MACCEs (OR 1.72, 95% confidence interval [CI] 1.15 to 2.56, p ϭ 0.008). However, DM remained associated with HF after controlling for age, previous MI, previous unstable angina, previous stable angina, hypertension, abnormal results on index electrocardiography, and left bundle branch block (OR 2.42, 95% CI 1.52 to 3.85, p Ͻ0.001).
Patients with DM were at greater risk (unadjusted hazard ratio [HR] 2.15, 95% CI 1.87 to 2.48, p Ͻ0.001) for MACCEs on long-term follow-up (Figure 1 ). At 7 years of follow-up, there were 227 MACCEs in patients with DM (71%, 95% CI 66% to 76%) and 779 MACCEs in patients without DM (45%, 95% CI 43% to 48%; Table 3 ). In a multivariate model, the significant association between DM and longterm MACCEs persisted (Table 4) . There was a significant interaction (p ϭ 0.032) between age and DM, such that the effect of DM on long-term MACCEs was more pronounced in younger patients (age Ͻ50 years, HR 3.19, 95% CI 1.65 to 6.18) than in older patients (age Ն90 years, HR 0.80, 95% CI 0.45 to 1.41). In addition, the adverse effect of DM on MACCEs was more pronounced in women. This gender effect was not secondary to differences in the rates of revascularization. At In multivariate analysis, DM was not associated with a significant effect on 30-day mortality (OR 1.43, 95% CI 0.75 to 2.72, p ϭ 0.28). In multivariate analysis, after controlling for age, previous MI, stable angina, hypertension, abnormal electrocardiographic results, systolic blood pressure, and index MI, DM was not associated with a significant effect on 30-day mortality (OR 1.28, CI 0.85 to 1.95, p ϭ 0.24). At intermediate and long-term follow-up, DM adversely affected survival. The median survival in patients with DM ( Figure 2 ) was 7.5 years compared with 16.5 years in those without DM (HR 2.45, 95% CI 2.14 to 2.81, p Ͻ0.001). At the end of follow-up, 272 patients with DM (81.9%) compared with 936 (49.2%) without DM had died (p Ͻ0.001). In a multivariate model, DM was associated with a significant increase in long-term mortality, with different effects depending on age (Table 5) . Similar to the model results for MACCEs, this effect was less pronounced in older patients compared with patients aged Ͻ50 years, in whom there was a strong association with follow-up mortality (HR 4.70, 95% CI 1.56 to 14.1, p ϭ 0.006), which decreased with increasing age. In patients aged Ն90 years, the association was not significant (HR 1.08, 95% CI 0.71 to 1.63, p ϭ 0.73).
In an unadjusted comparison of patients with DM with low to moderate AHCPR risk and patients without DM with high AHCPR risk, survival was similar for the first 8 years (Figure 3) . A divergence in the Kaplan-Meier curve after this time resulted in a significant difference between the 2 groups (HR 1.29, 95% CI 1.07 to 1.56, p ϭ 0.009), with low-to moderate-risk patients with DM faring worse than high-risk patients without DM. Patients with DM meeting high-risk AHCPR criteria performed consistently worse than the 2 groups. 
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Discussion
Cardiovascular outcomes in patients with DM presenting with ACS have been described in data from trials and registries, 1-3,9 -12 focusing primarily on short-term outcomes and with conflicting results. Patients with DM with ACS managed invasively have also demonstrated higher rates of composite ischemia and major bleeding, as evidenced by an analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. 13 Our study is unique in that it consisted of a large, consecutive, community-based cohort of patients with short-and longterm follow-up, and it was largely free of selection bias.
On short-term follow-up at 30 days, we found that unselected patients with DM presenting with acute ischemic chest pain had a higher crude rate of death and stroke. The baseline characteristics and short-term findings from large ACS registries are similar to those of our study, suggesting that registry data provide a good representation of day-today practice and outcomes. In-hospital data from the Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry reveal a higher crude rate of death and stroke in patients with DM, without any increase in MI. 1 The Global Registry of Acute Coronary Events (GRACE) registry reported that younger patients with DM and those receiving insulin were more likely to die. 10 The Euro Heart Survey of ACS demonstrated increased in-hospital mortality in women with DM, but not in men with DM. 11 This variable effect of gender on short-term mortality and MACCEs was not observed in our cohort.
In a multivariate model, the 30-day data from our cohort of patients with DM did not demonstrate an independent effect of DM on MACCEs. However, multivariate analysis in patients with DM can potentially underestimate the inherent cardiovascular risk posed by DM. This is likely the result of unintended statistical overadjustment for variables such as hypertension, obesity, previous revascularization, chronic kidney disease, and other co-morbidities, present more frequently in patients with DM. The higher risk for stroke in our cohort of patients with DM in the short term may be explained by the higher coexisting rates of hypertension, coronary bypass, and extensive atherosclerosis. Unlike our study, multivariate-adjusted pooled trial data from 11 TIMI studies revealed that patients with DM with ACS had a higher risk for death at 30 days. 3 This difference may be explained by the preferential enrollment of higher risk populations in the constituent TIMI trials.
The higher incidence of new-onset HF at 30 days in patients with DM in our study has been previously observed in the GRACE and OASIS registries. 1, 10 This excess risk for HF in patients with DM has been postulated to arise from disturbances in microvascular circulation, abnormalities in myocardial glucose and free fatty acid metabolism, and hyperglycemia-induced myocyte necrosis, apoptosis, and fibrosis. 14 Longer term follow-up data in unselected patients with DM presenting with index episodes of ACS are nonexistent. Our study is unique in that it provides long-term follow-up, to a median of 7.3 years for MACCEs and 16.6 years for mortality, in patients with DM with non-ST elevation ACS. The longest previous follow-up of 4 years in 170 patients with DM and ACS, from the Prospective Registry of Acute Ischaemic Syndromes in the United Kingdom (PRAIS-UK), failed to find a significant independent effect of DM on mortality. Pooled data from 5 TIMI studies did not reveal DM to be an independent predictor of death at 1 year. 12 The heterogeneity and generally higher risk of studies pooled for analysis limits their generalizability. However, 2-year findings of the unselected OASIS registry showed that DM was associated with significantly higher mortality, similar to our study.
It was also evident from our analysis that the adverse cardiovascular effect of DM was most pronounced in younger patients. The absence of an independently adverse cardiovascular effect of DM in patients aged Ն90 years is likely to have been caused by a higher burden of co-morbid cardiovascular conditions. The increased long-term MACCE rate associated with DM in women in the longterm is consistent with findings from the OASIS registry. 1 Also critically important was the prognoses of the patients with DM, comparable with those of patients without DM classified as at high risk by AHCPR criteria. These data emphasize the need for aggressive risk assessment and management in patients with DM, the institution of evidencebased therapies, and the development of DM-specific treatments that can ameliorate accelerated atherosclerosis and exaggerated thrombosis.
We acknowledge some limitations in our study. The diagnosis of DM was based on review of medical records. Information about the duration and control of DM, baseline left ventricular function, history of HF, and renal function was unavailable. Because data were collected retrospectively, undiagnosed patients with DM may have been misclassified at the outset. This misclassification likely resulted in an overestimation of MACCE rates in patients without DM. In addition, no data were available on patients who may have developed DM during the course of the long follow-up period. It can be argued that the demographic and patient adherence patterns in Olmsted County are not entirely representative of epidemiologic and disease patterns in other parts of the United States. Although this is well recognized, evidence from international studies argues against perceived differences in the impact of risk factors for coronary artery disease between different racial and cultural groups. 15, 16 Another important limitation of our study is the lack of data on treatment modalities in patients with DM, as it has been well reported that evidence-based therapies remain underused in patients with DM with ACS. 10, 17 Finally, the lack of troponin assay at the time of the study likely underestimated the proportion of patients with non-ST elevation MIs.
